These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 32954754)

  • 1. Xuebijing injection in the treatment of COVID-19: a retrospective case-control study.
    Guo H; Zheng J; Huang G; Xiang Y; Lang C; Li B; Huang D; Sun Q; Luo Y; Zhang Y; Huang L; Fang W; Zheng Y; Wan S
    Ann Palliat Med; 2020 Sep; 9(5):3235-3248. PubMed ID: 32954754
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Effect of Xuebijing injection on inflammatory markers and disease outcome of coronavirus disease 2019].
    Wen L; Zhou Z; Jiang D; Huang K
    Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2020 Apr; 32(4):426-429. PubMed ID: 32527346
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of Anluohuaxian in the treatment of patients with severe Coronavirus disease 2019- a multicenter, open label, randomized controlled study: a structured summary of a study protocol for a randomised controlled trial.
    Zhang C; Li J; Wu Z; Wang H; Que C; Zhao H; Wang G
    Trials; 2020 Jun; 21(1):495. PubMed ID: 32513299
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The study on the treatment of Xuebijing injection (XBJ) in adults with severe or critical Corona Virus Disease 2019 and the inhibitory effect of XBJ against SARS-CoV-2.
    Ma Q; Qiu M; Zhou H; Chen J; Yang X; Deng Z; Chen L; Zhou J; Liao Y; Chen Q; Zheng Q; Cai L; Shen L; Yang Z
    Pharmacol Res; 2020 Oct; 160():105073. PubMed ID: 32653650
    [No Abstract]   [Full Text] [Related]  

  • 5. Longitudinal COVID-19 profiling associates IL-1RA and IL-10 with disease severity and RANTES with mild disease.
    Zhao Y; Qin L; Zhang P; Li K; Liang L; Sun J; Xu B; Dai Y; Li X; Zhang C; Peng Y; Feng Y; Li A; Hu Z; Xiang H; Ogg G; Ho LP; McMichael A; Jin R; Knight JC; Dong T; Zhang Y
    JCI Insight; 2020 Jul; 5(13):. PubMed ID: 32501293
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of the Inflammatory Response to Severe COVID-19 Illness.
    McElvaney OJ; McEvoy NL; McElvaney OF; Carroll TP; Murphy MP; Dunlea DM; Ní Choileáin O; Clarke J; O'Connor E; Hogan G; Ryan D; Sulaiman I; Gunaratnam C; Branagan P; O'Brien ME; Morgan RK; Costello RW; Hurley K; Walsh S; de Barra E; McNally C; McConkey S; Boland F; Galvin S; Kiernan F; O'Rourke J; Dwyer R; Power M; Geoghegan P; Larkin C; O'Leary RA; Freeman J; Gaffney A; Marsh B; Curley GF; McElvaney NG
    Am J Respir Crit Care Med; 2020 Sep; 202(6):812-821. PubMed ID: 32584597
    [No Abstract]   [Full Text] [Related]  

  • 7. Yidu-toxicity blocking lung decoction ameliorates inflammation in severe pneumonia of SARS-COV-2 patients with Yidu-toxicity blocking lung syndrome by eliminating IL-6 and TNF-a.
    Zhao J; Yang X; Wang C; Song S; Cao K; Wei T; Ji Q; Zheng W; Li J; Zhou X; Liu J
    Biomed Pharmacother; 2020 Sep; 129():110436. PubMed ID: 32768938
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of the Adjuvant Efficacy of Natural Herbal Medicine on COVID-19: A Retrospective Matched Case-Control Study.
    Zhang HT; Huang MX; Liu X; Zheng XC; Li XH; Chen GQ; Xia JY; Hong ZS
    Am J Chin Med; 2020; 48(4):779-792. PubMed ID: 32420751
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An inflammatory cytokine signature predicts COVID-19 severity and survival.
    Del Valle DM; Kim-Schulze S; Huang HH; Beckmann ND; Nirenberg S; Wang B; Lavin Y; Swartz TH; Madduri D; Stock A; Marron TU; Xie H; Patel M; Tuballes K; Van Oekelen O; Rahman A; Kovatch P; Aberg JA; Schadt E; Jagannath S; Mazumdar M; Charney AW; Firpo-Betancourt A; Mendu DR; Jhang J; Reich D; Sigel K; Cordon-Cardo C; Feldmann M; Parekh S; Merad M; Gnjatic S
    Nat Med; 2020 Oct; 26(10):1636-1643. PubMed ID: 32839624
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Broncho-alveolar inflammation in COVID-19 patients: a correlation with clinical outcome.
    Pandolfi L; Fossali T; Frangipane V; Bozzini S; Morosini M; D'Amato M; Lettieri S; Urtis M; Di Toro A; Saracino L; Percivalle E; Tomaselli S; Cavagna L; Cova E; Mojoli F; Bergomi P; Ottolina D; Lilleri D; Corsico AG; Arbustini E; Colombo R; Meloni F
    BMC Pulm Med; 2020 Nov; 20(1):301. PubMed ID: 33198751
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Study on treatment of "cytokine storm" by anti-2019-nCoV prescriptions based on arachidonic acid metabolic pathway].
    Ren Y; Yao MC; Huo XQ; Gu Y; Zhu WX; Qiao YJ; Zhang YL
    Zhongguo Zhong Yao Za Zhi; 2020 Mar; 45(6):1225-1231. PubMed ID: 32281329
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Mechanism and Clinical Outcome of patients with Corona Virus Disease 2019 Whose Nucleic Acid Test has changed from negative to positive, and the therapeutic efficacy of Favipiravir: A structured summary of a study protocol for a randomised controlled trial.
    Li J; Zhang C; Wu Z; Wang G; Zhao H
    Trials; 2020 Jun; 21(1):488. PubMed ID: 32503657
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outpatient treatment of COVID-19 with steroids in the phase of mild pneumonia without the need for admission as an opportunity to modify the course of the disease: A structured summary of a randomised controlled trial.
    Saiz-Rodríguez M; Peña T; Lázaro L; González Á; Martínez A; Cordero JA; Vicente JT; Richard F; Coma MJ; de Frutos M; Labrador J; Pueyo A
    Trials; 2020 Jul; 21(1):632. PubMed ID: 32646502
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effective treatment of severe COVID-19 patients with tocilizumab.
    Xu X; Han M; Li T; Sun W; Wang D; Fu B; Zhou Y; Zheng X; Yang Y; Li X; Zhang X; Pan A; Wei H
    Proc Natl Acad Sci U S A; 2020 May; 117(20):10970-10975. PubMed ID: 32350134
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Evaluation of clinical value of Xuebijing combined with human immunoglobulin in severe and critically ill patients with coronavirus disease 2019].
    Chen L; Zhang A; Li Q; Cui Y; Yuan G
    Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2021 Apr; 33(4):399-404. PubMed ID: 34053480
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical features and treatment of COVID-19 patients in northeast Chongqing.
    Wan S; Xiang Y; Fang W; Zheng Y; Li B; Hu Y; Lang C; Huang D; Sun Q; Xiong Y; Huang X; Lv J; Luo Y; Shen L; Yang H; Huang G; Yang R
    J Med Virol; 2020 Jul; 92(7):797-806. PubMed ID: 32198776
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Corticosteroid therapy for patients with severe novel Coronavirus disease 2019.
    Ma Q; Qi D; Deng XY; Yuan GD; Tian WG; Cui Y; Yan XF; Wang DX
    Eur Rev Med Pharmacol Sci; 2020 Aug; 24(15):8194-8201. PubMed ID: 32767349
    [TBL] [Abstract][Full Text] [Related]  

  • 18. IL-6 Inhibitors in the Treatment of Serious COVID-19: A Promising Therapy?
    Atal S; Fatima Z
    Pharmaceut Med; 2020 Aug; 34(4):223-231. PubMed ID: 32535732
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical characteristics and predictors of survival in adults with coronavirus disease 2019 receiving tocilizumab.
    Morrison AR; Johnson JM; Griebe KM; Jones MC; Stine JJ; Hencken LN; To L; Bianchini ML; Vahia AT; Swiderek J; Ramesh MS; Peters MA; Smith ZR
    J Autoimmun; 2020 Nov; 114():102512. PubMed ID: 32646770
    [TBL] [Abstract][Full Text] [Related]  

  • 20. IL-6 and CD8+ T cell counts combined are an early predictor of in-hospital mortality of patients with COVID-19.
    Luo M; Liu J; Jiang W; Yue S; Liu H; Wei S
    JCI Insight; 2020 Jul; 5(13):. PubMed ID: 32544099
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.